Activated clotting time during cardiopulmonary bypass: Is repetition necessary during open heart surgery?

Asian Cardiovascular and Thoracic Annals

Volumn 12, Issue 1, 2004, Pages 47-52

  Neema, Praveen Kumar ^a   Sinha, Prabhat Kumar ^a   Rathod, Ramesh Chandra ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PROTAMINE;

ANTICOAGULATION; ARTICLE; BLOOD CLOT; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYSTALLOID; DRUG EFFICACY; DRUG HALF LIFE; DRUG SENSITIVITY; EXTRACORPOREAL CIRCULATION; FEMALE; HEPARINIZATION; HUMAN; HYPOTHERMIA; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; OXYGENATOR; PATIENT MONITORING; PATIENT SELECTION; PULSATILE FLOW; SURGICAL PATIENT;

EID: 2542536005     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230401200112     Document Type: Article

References (22)

1. Spiess BD, Silvay G. Overview of myocardial outcome: the interrelationships among coagulation, inflammation, and endothelium. J Cardiothorac Vasc Anesth 2000;14:2-5.
2. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth 1999;13:18-29.
3. Lesserson LS, Gravlee GP. Anticoagulation for cardiopulmonary bypass, in Gravlee GP (ed). Cardiopulmonary bypass Principles and Practice, Philadelphia, PA, Lippincott Williams and Wilkins 2000, pp 435-72.
4. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
5. Hunt BJ, Segal HC, Yacoub M. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104:211-2.
6. Shore-Lesserson L. Myocardial injury in cardiac surgery: the role of transfusion. J Cardiothorac Vasc Anesth 2000;14:11-4.
7. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-40.
8. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-84.
9. Bull BS, Huse WM, Brauer FS Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose response curve to individualize heparin and protamine doses. J Thorac Cardiovasc Surg 1975;69:685-9.
10. Horkay F, Martin P, Rajah SM, Walker DR. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg 1992;53:822-6.
11. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
12. Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990;99:518-27.
13. Dauchot PJ, Berzina-Moettus L, Rabinovitch A, Ankeney JL. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass. Anesth Analg 1983;62:710-9.
14. Umlas J, Gauvin G, Taff R. Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay. Ann Thorac Surg 1984;37:301-3.
15. Nielsen LE, Bell WR, Borkon AM, Neill CA. Extensive thrombus formation with heparin resistance during extracorporeal circulation. A new presentation of familial antithrombin III deficiency. Arch Intern Med 1987;147:149-52.
16. Menges T, Wagner RM, Welters I, Ruwoldt R, Boldt J, Hempelmann G. The role of the protein C-thrombomodulin system and fibrinolysis during cardiovascular surgery: influence of acute preoperative plasmapheresis. J Cardiothorac Vasc Anesth 1996;10:482-9.
17. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Med Scand 1963;173:619-30.
18. Nicholson SC, Keeling DM, Sinclair ME, Evans RD. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass. Br J Anaesth 2001;87:844-7.
19. Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Kater K, Goodnough LT, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective randomized evaluation in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1995;110:46-54.
20. Metz S, Keats AS. Low activated clotting time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990;49:440-4.
21. Moorman RM, Zapol WM, Lowenstein E. Neutralization of heparin anticoagulation, in Gravlee GP (ed). Cardiopulmonary bypass Principles and Practice, Baltimore, MD, Williams and Wilkins 1993, pp 381-2.
22. Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet activity. Anesthesiology 1997;86:1382-86.